PINEALON

Cognitive EnhancementResearch Only

Limited but intriguing human data from Russian studies, though the lack of randomized controlled trials makes it difficult to draw firm conclusions about efficacy.

Primarily investigated by Russian researchers studying peptide bioregulators and aging, with some interest from longevity-focused research groups examining circadian rhythm dysfunction.

FDA Status

Research Only

Since Feb 2026

Evidence

Moderate

Studies

8 total, 4 human

What is PINEALON?

Among the handful of tripeptides emerging from Russian longevity research, this short-chain compound has garnered attention for its apparent selectivity toward brain tissue and the pineal gland. Researchers have focused on its potential role in counteracting age-related decline in neurological function, particularly the gradual deterioration of the pineal gland's melatonin production that occurs with aging.

The peptide appears to work at the genetic level, influencing gene expression patterns within brain cells and specifically targeting the pineal gland's regulatory pathways. Think of it as a molecular signal that helps aging brain tissue remember how to function more like younger tissue, particularly in maintaining the circadian rhythm machinery that depends on proper melatonin synthesis.

What the Research Shows

Six human studies provide some clinical insight, but the absence of randomized controlled trials significantly limits the strength of conclusions that can be drawn.

Eight studies (6 human, 0 randomized controlled trials) examined PINEALON, primarily investigating its effects on aging markers and stress-related conditions. Key findings included anabolic effects and reduced aging rates in elderly patients with multiple comorbidities, improvements in psychoemotional status and occupational stress in truck drivers, and favorable safety profiles when combined with other oligopeptides like Vesugen.